The Cooper Companies (COO)
(Delayed Data from NSDQ)
$106.80 USD
+1.19 (1.13%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $106.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.80 USD
+1.19 (1.13%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $106.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth F Momentum D VGM
Zacks News
Strength Seen in The Cooper Companies (COO): Can Its 7.8% Jump Turn into More Strength?
by Zacks Equity Research
The Cooper Companies (COO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
HSIC vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. COO: Which Stock Is the Better Value Option?
3 Stocks to Tap the Promising Dental Supplies Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical-Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
HSIC vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HSIC vs. COO: Which Stock Is the Better Value Option?
HSIC vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HSIC vs. COO: Which Stock Is the Better Value Option?
Cooper Companies (COO) Q2 Earnings Top Estimates, '21 View Up
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter 2021 earnings reflect solid segmental performance.
Abbott (ABT) Downgrades 2021 Outlook on Lower Testing Demand
by Zacks Equity Research
Abbott's (ABT) revised 2021 forecast continues to reflect strong, double-digit EPS growth despite lower COVID-19 testing demand.
Myriad Genetics (MYGN) Sells myPath to Focus on Core Units
by Zacks Equity Research
Myriad Genetics' (MYGN) new divesture will provide the company with growth capital for future investments.
Quest Diagnostics (DGX) Buys Outreach Lab, Widens Midwest Base
by Zacks Equity Research
Mercy's outreach laboratory services are set to get integrated into Quest Diagnostics' (DGX) full-service laboratory in Lenexa, KS.
Integra (IART) Tissue Technologies Rebounds Amid Supply Woe
by Zacks Equity Research
Integra's (IART) CSS segment too reflects a gradual recovery in procedure-based market as well as an improvement in hospital capital spending during the first quarter.
Walgreens' (WBA) New Partnerships Aid, Retail Sales Dip
by Zacks Equity Research
Walgreens Boots' (WBA) response toward combatting the pandemic - conducting COVID-19 tests at various locations and actively participating in vaccinating residents and staff - is impressive.
Illumina (ILMN) Expands NIPT Offering With New Collaboration
by Zacks Equity Research
Illumina's (ILMN) VeriSeq NIPT Solution v2 provides accurate, consistent and scalable end-to-end genome-wide noninvasive prenatal testing.
Cooper Companies (COO) Unit's Ortho-K Lens Receives CE Mark
by Zacks Equity Research
Cooper Companies' (COO) unit CooperVision's latest orthokeratology contact lens becomes the latest myopia control product to gain European approval.
Here's Why You Should Add STERIS (STE) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about STERIS (STE) owing to strong segmental performance and huge growth potential in healthcare and pharmaceutical industries.
Cooper Companies (COO) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.
Myriad Genetics' (MYGN) GeneSight Test Rollout Initiated by IPM
by Zacks Equity Research
Myriad Genetics' (MYGN) GeneSight testing distribution initiated through IPM will help clinicians and patients assess individual's response to certain medications.
The Cooper Companies (COO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
The Cooper Companies (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Cooper Companies (COO) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
The Cooper Companies (COO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Masimo (MASI), Spacelabs Team Up to Enhance Patient Outcome
by Zacks Equity Research
Masimo's (MASI) extension of partnership with Spacelabs is expected to provide better patient outcomes with the accessibility of patient monitoring solutions.
Here's Why You Should Add Inogen (INGN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its direct-to-customer business model and a strong product portfolio.
Veeva (VEEV) Enhances Clinical Trial Management via Vault CTMS
by Zacks Equity Research
Veeva's (VEEV) Vault CTMS application is expected to aid global organizations to advance study execution while ensuring compliance.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on the DaVita (DVA) stock, courtesy of its solid prospects.
STERIS (STE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS (STE) is likely to have continued to gain from the robust demand of PPE and COVID-19-related products in Q4.
Merit Medical (MMSI) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merit Medical (MMSI) benefits from growth in revenues at the Cardiovascular segment in Q1.
DaVita (DVA) Q1 Earnings Beat Estimates, Revenues Miss Mark
by Zacks Equity Research
DaVita's (DVA) net dialysis and related lab-patient service revenues rise in Q1.